Abstract
Anti-tumour necrosis factor (TNF)-a agents have been increasingly used to treat patients affected by inflammatory bowel disease and dermatological and rheumatologic inflammatory disorders. However, the widening use of biologics is related to a new class of adverse events called paradoxical reactions. Its pathogenesis remains unclear, but it is suggested that cytokine remodulation in predisposed individuals can lead to the inflammatory process. Here, we dissect the clinical aspects and overall outcomes of autoimmune diseases caused by anti-TNF-a therapies.
| Original language | English |
|---|---|
| Pages (from-to) | 8187-N/A |
| Journal | International Journal of Molecular Sciences |
| Volume | 24 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 2023 |
All Science Journal Classification (ASJC) codes
- Catalysis
- Molecular Biology
- Spectroscopy
- Computer Science Applications
- Physical and Theoretical Chemistry
- Organic Chemistry
- Inorganic Chemistry
Keywords
- adalimumab
- autoimmune diseases
- certolizumab pegol
- etanercept
- golimumab
- inflammatory bowel disease
- infliximab
- paradoxical reactions
Fingerprint
Dive into the research topics of 'Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver